<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147897</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00006141</org_study_id>
    <secondary_id>1R01MH116057-01A1</secondary_id>
    <nct_id>NCT04147897</nct_id>
  </id_info>
  <brief_title>Implementing mHealth for Schizophrenia in Community Mental Health Settings</brief_title>
  <official_title>Implementing mHealth for Schizophrenia in Community Mental Health Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized control trial examining two mHealth intervention strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a multi-site site hybrid type III effectiveness/implementation
      study in Washington State. The study involves a systematic head-to-head comparison between
      External Facilitation (EF) and Internal Facilitation (IF) implementation models applied to
      the FOCUS mHealth intervention.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PhQ9</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The Patient Health Questionnaire (PHQ)-9 is the major depressive disorder (MDD) module of the full PHQ. Total scores range from 0-27. Higher scores represent worsening of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in GAD-7</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The Generalized Anxiety Disorder-7 measures generalized anxiety disorder. GAD-7 total score ranges from 0 to 21. Higher scores represent worsening of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Insomnia Severity Index</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The Insomnia Severity Index (ISI) is a brief screening assessment tool designed to evaluate insomnia.Total scores range from 0-28. Higher scores represent worsening of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Green Paranoid Thoughts Scale- ideas and persecution sub-scale</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The Green Paranoid Thoughts Scale (GPTS)- sub-scale: measures ideas of persecution. Scores range from 16-80. Higher scores represent worsening of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Symptom Check List SCL9</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>The Symptom Check List-9 is a brief version of the SCL-90, which aims to evaluate a broad range of psychological problems and symptoms of psychopathology. Total scores are calculated (sum of all responses) then divided by 9 for an average global score. Total sum scores range from 0-36. Average global scores range from 0-4. Higher scores mean more severe symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hamilton Program for Schizophrenia Voices Questionnaire (HPSVQ)</measure>
    <time_frame>0,3,6 Months</time_frame>
    <description>A 9-item measure specifically designed to quantify characteristics of auditory hallucinations including frequency, negative content, loudness, duration, interference with life, distress, impact on self-appraisal, and compliance with commands.Total score is a sum of all 9 items. Total HPSVQ scores range from 0-36. Higher scores mean more severe symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Illness Management and Recovery Scale</measure>
    <time_frame>0,3,6 months</time_frame>
    <description>IMRS measures illness management and recovery. Scoring is a sum of all responses ranging from 15-75. Higher scores mean more severe symptoms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Internal Facilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mHealth specialist is a trained clinician embedded in the clinical team offering the mHealth intervention, FOCUS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>External Facilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mHealth specialist is a trained clinician external to the clinical team offering the mHealth intervention, FOCUS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FOCUS</intervention_name>
    <description>FOCUS is a self management mHealth application for people with serious mental illness.</description>
    <arm_group_label>External Facilitation</arm_group_label>
    <arm_group_label>Internal Facilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All participants need to be receiving clinical care at participating clinics who have
        partnered with the research team for this study.

        Inclusion:

          1. Chart diagnosis of SSD (i.e., schizophrenia, schizoaffective disorder, schizotypal
             disorder, delusional disorder, or schizophreniform disorder;

          2. 18 years or older;

          3. English-speaking;

          4. Own a smartphone that can support FOCUS and active data plan.

        Exclusion:

          1. Used FOCUS in the past;

          2. Plan to move or discontinue services at participating clinics in the upcoming 6
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dror Ben-Zeev, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Brian, MPH</last_name>
    <phone>206-543-4427</phone>
    <email>rbrian@uw.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Dror Ben-Zeev</investigator_full_name>
    <investigator_title>Professor, School of Medicine: Psychiatry And Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

